ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 07/05/22

Arrowhead Pharmaceuticals ( NASDAQ: ARWR ) said it dosed the first patients in two phase 1/2a trials of its RNA interference candidates ARO-MUC5AC and ARO-RAGE, being explored to treat certain muco-obstructive and inflammatory pulmonary diseases. A phase 1/2a stud...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in two Phase 1/2a clinical trials of ARO-MUC5AC and ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutics designed to reduce production the of mucin 5AC (MUC5...

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong bet on a stock due for potential FDA approval in July. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valu...

Should Investors Be Watching These Top Biotech Stocks In The Stock Market Now? Just as most people think that pandemic woes are behind us, we now have the emergence of the monkeypox. While this virus may not be as contagious as the coronavirus, there is still a real cause for concer...

Arrowhead Pharmaceuticals ( ARWR ), a clinical-stage biotech focused on RNA interference (RNAi) therapeutics surged on above average volume on Wednesday in solidarity with several other drug developers targeting the liver disease, non-alcoholic steatohepatitis (NASH). Despite ...

Arrowhead is a leader in RNAi. ARWR has a vast platform. I will wait for the first approval before investing. For further details see: Arrowhead Pharma: We Can Afford To Wait For More Proof

Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues. This does not look attractive to us right now. For further details see: Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telli...

Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...

Takeda's total debt was $35,698.6 million, down 22.1% from the previous year. Takeda Pharmaceutical has a dividend yield of 5.15%, and Gilead Sciences has a dividend yield of 4.53%. Gilead's key HIV drug is beginning to feel increased competition from ViiV Healthcare's drug. T...

Amgen’s Lumakras revenue is ramping rapidly. Amgen Phase 2 topline olpasiran data was positive. Amgen rheumatoid arthritis biosimilar received FDA approval. For further details see: Amgen Compelling On New Data And Biosimilar Approval